Cholinesterase inhibitor treatment and urinary incontinence in Alzheimer's disease

被引：21
|
作者：
Starr, John M. [1 ]
机构：
[1] Univ Edinburgh, Royal Victoria Hosp, Geriatr Med Unit, Edinburgh, Midlothian, Scotland
来源：
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY | 2007年 / 55卷 / 05期
关键词：
D O I：
10.1111/j.1532-5415.2007.01143.x
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
引用
收藏
页码：800 / 801
页数：2
相关论文
共 50 条
  • [41] When do you stop a cholinesterase inhibitor in Alzheimer's disease?
    Brodaty, Henry
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2011, 1 (03) : 191 - 192
  • [42] Imaging patient response to cholinesterase inhibitor therapy in Alzheimer's disease
    Venneri, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 : 667 - 667
  • [43] Cerebral metabolic activation with cholinesterase inhibitor therapy in Alzheimer's disease
    Mega, M
    Dinov, I
    Manese, M
    O'Connor, SM
    Toga, A
    Cummings, JE
    Felix, J
    NEUROBIOLOGY OF AGING, 2002, 23 (01) : S114 - S114
  • [44] Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the Netherlands
    Caro, JJ
    Salas, M
    Ward, A
    Getsios, D
    Mehnert, A
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2002, 14 (02) : 84 - 89
  • [45] Cholinesterase inhibitor treatment increases phosphotau accumulation in Alzheimer's disease but reduces Aβ in dementia with Lewy bodies
    Chalmers, K.
    Wilcock, G.
    Vinters, H.
    Perry, E.
    Ballard, C.
    Love, S.
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2008, 34 : 3 - 3
  • [46] Increase in Platelet Immunoglobulin in Alzheimer's Disease is Normalised Following Cholinesterase Inhibitor Treatment: Preliminary Results
    Mukaetova-Ladinska, Elizabeta B.
    Abdel-All, Zeinab
    Andrade, Joana
    McNally, Richard J. Q.
    James, Peter W.
    Kalaria, Raj N.
    O'Brien, John T.
    JOURNAL OF ALZHEIMERS DISEASE, 2012, 32 (02) : 431 - 436
  • [47] A randomized phase I study of methanesulfonyl fluoride, an irreversible cholinesterase inhibitor, for the treatment of Alzheimer's disease
    Moss, Donald E.
    Fariello, Ruggero G.
    Sahlmann, Joerg
    Sumaya, Isabel
    Pericle, Federica
    Braglia, Enrico
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 75 (05) : 1231 - 1239
  • [48] Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease
    Rösler, M
    Retz, W
    Retz-Junginger, P
    Dennler, HJ
    BEHAVIOURAL NEUROLOGY, 1998, 11 (04) : 211 - 216
  • [49] Pharmacoeconomics of Alzheimer’s disease (AD) treatment with cholinesterase inhibitors
    Jan Versijpt
    Acta Neurologica Belgica, 2012, 112 : 141 - 145
  • [50] Selectivity of Cholinesterase InhibitionClinical Implications for the Treatment of Alzheimer’s Disease
    Marta Weinstock
    CNS Drugs, 1999, 12 : 307 - 323
12345